Challenges have been recognized in healthcare of patients with Alzheimer’s disease (AD) in the COVID-19 pandemic, given a high infection and mortality rate of COVID-19 in these patients. This situation urges the identification of underlying risks and preferably biomarkers for evidence-based, more effective healthcare. Towards this goal, current literature review and network analysis synthesize available information on the AD-related gene APOE into four lines of mechanistic evidence. At a cellular level, the risk isoform APOE4 confers high infectivity by the underlying coronavirus SARS-CoV-2; at a genetic level, APOE4 is associated with severe COVID-19; at a pathway level, networking connects APOE with COVID-19 risk factors such as ACE2, TMPRSS2, NRP1, and LZTFL1; at a behavioral level, APOE4-associated dementia may increase the exposure to coronavirus infection which causes COVID-19. Thus, APOE4 could exert multiple actions for high infection and mortality rates of the patients, or generally, with COVID-19.
【저자키워드】 COVID-19, coronavirus, Biomarker, Comorbidity, APOE4, Peripheral mechanisms, 【초록키워드】 Coronavirus infection, ACE2, TMPRSS2, coronavirus, severe COVID-19, COVID-19 pandemic, Genetic, Infection, risk, risk factor, Alzheimer’s disease, Dementia, healthcare, challenge, Patient, pathway, APOE4, network analysis, NRP1, mortality rate, information, patients, ApoE, cellular, Evidence, exposure to, literature review, networking, LZTFL1, isoform, effective, cause, with COVID-19,